Exciting alternatives: An overview of long-acting HIV treatment, prevention

Acknowledging that even singletablet regimens may pose challenges to achieving viral suppression in many patients - including pill fatigue, tolerability, toxicity concerns and HIVrelated stigma - the focus has now shifted to long-acting (LA) ART. Oral lead-in therapy may be pursued to ensure tolerab...

Full description

Saved in:
Bibliographic Details
Published in:Infectious Disease News 2022-10, Vol.35 (10), p.5-5
Main Authors: Parisi, Michael J, Ross, Jennifer
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Drug dosages
FDA approval
Hispanic Americans
HIV
Human immunodeficiency virus
Infectious diseases
Minority & ethnic groups
Patient satisfaction
Prevention
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acknowledging that even singletablet regimens may pose challenges to achieving viral suppression in many patients - including pill fatigue, tolerability, toxicity concerns and HIVrelated stigma - the focus has now shifted to long-acting (LA) ART. Oral lead-in therapy may be pursued to ensure tolerability, and similar to cabotegravir/rilpivirine in combination, it is well tolerated, with the most common adverse reaction being injection site reactions. The International Partnership for Microbicides (IPM) withdrew its new drug application for FDA consideration because of the unlikelihood of approval in the U.S., a move that primarily affected women of racial and ethnic minority groups in a country where they are already disproportionately affected and may benefit the most.
ISSN:1056-9251